What is the share price of Hester Biosciences Ltd (HESTERBIO) today?
The share price of HESTERBIO as on 20th May 2025 is ₹1833.90. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Hester Biosciences Ltd (HESTERBIO) share?
The past returns of Hester Biosciences Ltd (HESTERBIO) share are- Past 1 week: 8.28%
- Past 1 month: 2.09%
- Past 3 months: 14.87%
- Past 6 months: -24.36%
- Past 1 year: 5.52%
- Past 3 years: -20.86%
- Past 5 years: 65.19%
What are the peers or stocks similar to Hester Biosciences Ltd (HESTERBIO)?
The peers or stocks similar to Hester Biosciences Ltd (HESTERBIO) include:What is the dividend yield % of Hester Biosciences Ltd (HESTERBIO) share?
The current dividend yield of Hester Biosciences Ltd (HESTERBIO) is 0.38.What is the market cap of Hester Biosciences Ltd (HESTERBIO) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Hester Biosciences Ltd (HESTERBIO) is ₹1568.24 Cr as of 20th May 2025.What is the 52 week high and low of Hester Biosciences Ltd (HESTERBIO) share?
The 52-week high of Hester Biosciences Ltd (HESTERBIO) is ₹3379 and the 52-week low is ₹1242.95.What is the PE and PB ratio of Hester Biosciences Ltd (HESTERBIO) stock?
The P/E (price-to-earnings) ratio of Hester Biosciences Ltd (HESTERBIO) is 57.03. The P/B (price-to-book) ratio is 5.18.Which sector does Hester Biosciences Ltd (HESTERBIO) belong to?
Hester Biosciences Ltd (HESTERBIO) belongs to the Health Care sector & Biotechnology sub-sector.How to buy Hester Biosciences Ltd (HESTERBIO) shares?
You can directly buy Hester Biosciences Ltd (HESTERBIO) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Hester Biosciences Ltd
HESTERBIO Share Price
HESTERBIO Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
HESTERBIO Performance & Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
57.07 | 5.18 | 0.38% |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
44.82 | 6.38 | 0.56% |
HESTERBIO Analyst Ratings & Forecast
Price Upside
Earnings Growth
Rev. Growth
HESTERBIO Company Profile
Hester Biosciences Limited is engaged in manufacturing of poultry vaccines and large animal vaccines, and trading of poultry health products and large animal health products. Its segments include Poultry Division and Large Animal Division.
HESTERBIO Similar Stocks (Peers)
Compare with peersHESTERBIO Sentiment Analysis
HESTERBIO Stock Summary · February 2025
In Q3 FY25, the company faced significant challenges, including a 6% decline in divisional product sales and a 24% drop in the Animal Healthcare System, largely due to external pressures like lower milk prices and regulatory bans. However, an impressive 85% year-on-year profit increase for the first nine months was driven by operational efficiencies and foreign exchange gains. The Petcare division thrived with a 105% sales surge, reflecting strong market potential, while the Poultry Healthcare segment benefited from heightened disease awareness. Despite a dip in consolidated EBITDA, management remains optimistic about long-term growth, particularly in the Petcare sector, and is committed to innovation and strategic expansion, especially in the African market.
Key Points on Hesterbio Stock
HESTERBIO Stock Growth Drivers
7Strong Financial Performance
Hester Biosciences Limited has reported significant financial achievements, including a year-on-year profitability growth of 85%
Growth in Poultry Healthcare Division
The Poultry Healthcare division has shown strong performance, with sales increasing by 12% in Q3
HESTERBIO Stock Challenges
4Decline in Financial Performance
Hester Biosciences reported disappointing financial results, with a consolidated EBITDA of Rs. 5 crore, the
Sales Decline in Key Divisions
The Animal Healthcare System experienced a 24% decline in sales for Q3, although it maintained
HESTERBIO Forecasts
HESTERBIO Forecast
HESTERBIO
Income
Balance Sheet
Cash Flow
HESTERBIO Income Statement
Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 123.53 | 138.49 | 185.28 | 189.64 | 219.01 | 249.17 | 285.65 | 319.80 | 319.13 | 319.13 | ||||||||||
Raw Materials | 29.11 | 35.39 | 41.92 | 44.15 | 46.63 | 75.41 | 82.74 | 87.14 | 250.05 | 250.05 | ||||||||||
Power & Fuel Cost | 5.59 | 6.37 | 7.83 | 8.13 | 7.57 | 10.28 | 12.74 | 15.30 | ||||||||||||
Employee Cost | 18.32 | 23.24 | 28.93 | 40.65 | 38.92 | 45.33 | 56.02 | 64.13 | ||||||||||||
Selling & Administrative Expenses | 15.93 | 17.92 | 24.99 | 37.78 | 35.47 | 40.18 | 54.77 | 56.48 | ||||||||||||
Operating & Other expenses | 13.15 | 5.75 | 6.36 | -2.85 | 20.41 | 3.82 | 9.22 | 27.85 | ||||||||||||
EBITDA | 41.43 | 49.82 | 75.25 | 61.78 | 70.01 | 74.15 | 70.16 | 68.90 | 69.08 | 69.08 | ||||||||||
Depreciation/Amortization | 7.00 | 9.66 | 11.76 | 13.07 | 13.31 | 16.58 | 20.70 | 17.17 | 16.80 | 16.80 | ||||||||||
PBIT | 34.43 | 40.16 | 63.49 | 48.71 | 56.70 | 57.57 | 49.46 | 51.73 | 52.28 | 52.28 | ||||||||||
Interest & Other Items | 3.50 | 4.04 | 6.63 | 7.37 | 6.60 | 4.06 | 9.32 | 19.78 | 12.70 | 12.71 | ||||||||||
PBT | 30.93 | 36.12 | 56.86 | 41.34 | 50.10 | 53.51 | 40.14 | 31.95 | 39.58 | 39.57 | ||||||||||
Taxes & Other Items | 7.38 | 10.51 | 15.29 | 12.16 | 15.68 | 14.17 | 13.53 | 13.07 | 12.08 | 12.09 | ||||||||||
Net Income | 23.55 | 25.61 | 41.57 | 29.18 | 34.42 | 39.34 | 26.61 | 18.88 | 27.50 | 27.48 | ||||||||||
EPS | 27.68 | 30.11 | 48.87 | 34.30 | 40.46 | 46.25 | 31.28 | 22.19 | 33.89 | 32.30 | ||||||||||
DPS | 5.30 | 10.00 | 11.00 | 6.60 | 10.00 | 10.00 | 8.00 | 6.00 | 7.00 | 6.00 | ||||||||||
Payout ratio | 0.19 | 0.33 | 0.23 | 0.19 | 0.25 | 0.22 | 0.26 | 0.27 | 0.21 | 0.19 |
HESTERBIO Company Updates
Annual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFHESTERBIO Past Performance & Peer Comparison
Health CareBiotechnology
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Hester Biosciences Ltd | 57.03 | 5.18 | 0.38% |
Biocon Ltd | 40.39 | 1.62 | 0.37% |
Onesource Specialty Pharma Ltd | -1,038.02 | 47.11 | — |
Sai Life Sciences Ltd | 91.78 | 16.01 | — |
HESTERBIO Stock Price Comparison
Compare HESTERBIO with any stock or ETFHESTERBIO Shareholdings
HESTERBIO Promoter Holdings Trend
In last 6 months, promoter holding in the company has almost stayed constant
Pledged promoter holdings is insignificant
HESTERBIO Institutional Holdings Trend
In last 3 months, retail holding in the company has almost stayed constant
In last 3 months, foreign institutional holding of the company has almost stayed constant
HESTERBIO Shareholding Pattern
HESTERBIO Shareholding History
Mutual Funds Invested in HESTERBIO
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 1 Mutual Funds holding Hester Biosciences Ltd
Funds (Top 1) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 0.0006% | Percentage of the fund’s portfolio invested in the stock 0.05% | Change in the portfolio weight of the stock over the last 3 months 0.00% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 94/109 (-6) |
Compare 3-month MF holding change on Screener
smallcases containing HESTERBIO stock
Looks like this stock is not in any smallcase yet.
HESTERBIO Events
HESTERBIO Dividend Trend
HESTERBIO has shown inconsistent dividend trend over the last 5 years
Current dividend yield is 0.38%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹3.80 every year
Dividends
Corp. Actions
Announcements
Legal Orders
HESTERBIO Upcoming Dividends
No upcoming dividends are available
HESTERBIO Past Dividends
Cash Dividend
Ex DateEx DateAug 22, 2024
Dividend/Share
₹6.00
Ex DateEx Date
Aug 22, 2024
Cash Dividend
Ex DateEx DateSep 13, 2023
Dividend/Share
₹8.00
Ex DateEx Date
Sep 13, 2023
Cash Dividend
Ex DateEx DateAug 11, 2022
Dividend/Share
₹10.00
Ex DateEx Date
Aug 11, 2022
Cash Dividend
Ex DateEx DateAug 5, 2021
Dividend/Share
₹10.00
Ex DateEx Date
Aug 5, 2021
Cash Dividend
Ex DateEx DateAug 27, 2020
Dividend/Share
₹6.60
Ex DateEx Date
Aug 27, 2020
HESTERBIO Stock News & Opinions
The Animal Division, which includes both Ruminants and Pet health products, reported an 8% growth in revenue to Rs 30.53 crore in Q4 FY25. The Poultry Healthcare division's revenue grew by 3% YoY to Rs 46.08 crore during the period under review. While EBITDA expanded by 8% YoY to Rs 14.76 crore, EBITDA margin remained constant at 19%. On a consolidated basis, the company has recorded 76% drop in net profit to Rs 1.54 crore even as a revenues increased by 3% to Rs 81.92 crore in Q4 FY25 over Q4 FY24. For FY25, Hester Bio has registered a net profit of Rs 28.82 crore (up 36% YoY) and revenue from operations of Rs 304.54 crore (up 2% YoY). In its outlook, the company said that it remains focused on deepening its presence across all core segments while maintaining strong operational discipline. The company is on track to launch the Avian Influenza vaccine and expand its portfolio of feed supplements and disinfectants in the Poultry Healthcare Division, creating new domestic and export opportunities. In the Animal Division, efforts will be on broadening the nutritional and therapeutic product range to meet evolving market needs and strengthen market share. Continued investments in product development, supply chain efficiency, and customer engagement will drive sustainable growth. Hester is also prioritising international expansion, with a strong focus on scaling its Africa operations and strengthening its presence in existing and new geographies, aligned with its long-term vision of global leadership in animal healthcare,' the company stated. Hester Biosciences Limited is one of the India's leading animal health company, manufacturing vaccines and health products. It is the second largest poultry vaccine manufacturer, with approximately 35% market share in India. The scrip slipped 3.20% to currently trade at Rs 1643.50 on the BSE. Powered by Capital Market - Live
Net profit of Hester Biosciences declined 73.94% to Rs 1.29 crore in the quarter ended March 2025 as against Rs 4.95 crore during the previous quarter ended March 2024. Sales rose 3.37% to Rs 81.93 crore in the quarter ended March 2025 as against Rs 79.26 crore during the previous quarter ended March 2024. For the full year,net profit rose 45.53% to Rs 27.49 crore in the year ended March 2025 as against Rs 18.89 crore during the previous year ended March 2024. Sales rose 2.15% to Rs 311.10 crore in the year ended March 2025 as against Rs 304.55 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales81.9379.26 3 311.10304.55 2 OPM %23.4120.09 -19.6317.62 - PBDT7.9213.61 -42 56.3749.13 15 PBT3.759.87 -62 39.5731.95 24 NP1.294.95 -74 27.4918.89 46 Powered by Capital Market - Live
Hester Biosciences announced that the Board of Directors of the Company at its meeting held on 9 May 2025, inter alia, have recommended the final dividend of Rs 7 per equity Share (i.e. 70%) , subject to the approval of the shareholders.Powered by Capital Market - Live
Hester Biosciences will hold a meeting of the Board of Directors of the Company on 9 May 2025.Powered by Capital Market - Live
Net profit of Hester Biosciences rose 192.96% to Rs 11.66 crore in the quarter ended December 2024 as against Rs 3.98 crore during the previous quarter ended December 2023. Sales declined 5.61% to Rs 63.22 crore in the quarter ended December 2024 as against Rs 66.98 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales63.2266.98 -6 OPM %8.0215.15 - PBDT17.6610.16 74 PBT13.376.41 109 NP11.663.98 193 Powered by Capital Market - Live
Hester Biosciences will hold a meeting of the Board of Directors of the Company on 30 January 2025.Powered by Capital Market - Live
Hester Biosciences has received reaffirmation in credit ratings for bank facilities at CARE BBB+; Stable / CARE A2 from CARE Ratings. Powered by Capital Market - Live
Net profit of Hester Biosciences rose 100.49% to Rs 8.20 crore in the quarter ended September 2024 as against Rs 4.09 crore during the previous quarter ended September 2023. Sales rose 18.78% to Rs 83.69 crore in the quarter ended September 2024 as against Rs 70.46 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales83.6970.46 19 OPM %22.8918.75 - PBDT16.0711.05 45 PBT11.876.76 76 NP8.204.09 100 Powered by Capital Market - Live
Hester Biosciences will hold a meeting of the Board of Directors of the Company on 28 October 2024.Powered by Capital Market - Live
Net profit of Hester Biosciences rose 8.01% to Rs 6.34 crore in the quarter ended June 2024 as against Rs 5.87 crore during the previous quarter ended June 2023. Sales declined 6.35% to Rs 82.27 crore in the quarter ended June 2024 as against Rs 87.85 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales82.2787.85 -6 OPM %21.4516.35 - PBDT14.7314.31 3 PBT10.598.91 19 NP6.345.87 8 Powered by Capital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 11.53%, vs industry avg of 19.04%
Over the last 5 years, market share decreased from 2.42% to 1.73%
Over the last 5 years, net income has grown at a yearly rate of -14.6%, vs industry avg of 2.04%